| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| V A Gault, N Irwin, P Harriott, P R Flatt, F P M O'Hart. DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser2-Asp13)GIP. Cell biology international. vol 27. issue 1. 2003-08-28. PMID:12713798. |
the peptide failed to display antagonistic properties as it did not significantly alter insulin secretion when incubated in the presence of gip (10(-7)mol/l). |
2003-08-28 |
2023-08-12 |
Not clear |
| B Messenger, M N Clifford, L M Morga. Glucose-dependent insulinotropic polypeptide and insulin-like immunoreactivity in saliva following sham-fed and swallowed meals. The Journal of endocrinology. vol 177. issue 3. 2003-08-11. PMID:12773121. |
gastrointestinal peptides, including insulin, glucagon and glucose-dependent insulinotropic polypeptide (gip) have previously been reported in salivary glands. |
2003-08-11 |
2023-08-12 |
human |
| B Messenger, M N Clifford, L M Morga. Glucose-dependent insulinotropic polypeptide and insulin-like immunoreactivity in saliva following sham-fed and swallowed meals. The Journal of endocrinology. vol 177. issue 3. 2003-08-11. PMID:12773121. |
salivary and plasma levels of immunoreactive insulin, gip and glucagon-like peptide-1 (glp-1), total protein, alpha-amylase, glucose and non-esterified fatty acid were measured before and for 90 min following the meals. |
2003-08-11 |
2023-08-12 |
human |
| B Messenger, M N Clifford, L M Morga. Glucose-dependent insulinotropic polypeptide and insulin-like immunoreactivity in saliva following sham-fed and swallowed meals. The Journal of endocrinology. vol 177. issue 3. 2003-08-11. PMID:12773121. |
these findings are consistent with insulin in saliva being an ultrafiltrate of that circulating in blood, but gip in saliva being the product of local salivary gland synthesis, whose secretion is influenced, directly or indirectly, by oral stimuli. |
2003-08-11 |
2023-08-12 |
human |
| Gyeong Jae Cho, Sun Ryu, Young Hee Kim, Yoon Sook Kim, Eun Woo Cheon, Jong Moon Park, Hyun Joon Kim, Sang Soo Kang, Wan Sung Cho. Upregulation of glucose-dependent insulinotropic polypeptide and its receptor in the retina of streptozotocin-induced diabetic rats. Current eye research. vol 25. issue 6. 2003-08-05. PMID:12789546. |
gip is a secreted protein, known to be released from the small intestine, which potentiates glucose-induced insulin secretion from the pancreas. |
2003-08-05 |
2023-08-12 |
rat |
| Victor A Gault, Finbarr P M O'Harte, Patrick Harriott, Peter R Flat. Degradation, cyclic adenosine monophosphate production, insulin secretion, and glycemic effects of two novel N-terminal Ala2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo. Metabolism: clinical and experimental. vol 52. issue 6. 2003-07-11. PMID:12800091. |
glucose-dependent insulinotropic polypeptide (gip) has significant potential in diabetes therapy due to its ability to serve as a glucose-dependent activator of insulin secretion. |
2003-07-11 |
2023-08-12 |
mouse |
| Victor A Gault, Finbarr P M O'Harte, Patrick Harriott, Peter R Flat. Degradation, cyclic adenosine monophosphate production, insulin secretion, and glycemic effects of two novel N-terminal Ala2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo. Metabolism: clinical and experimental. vol 52. issue 6. 2003-07-11. PMID:12800091. |
in brin-bd11 cells, both (abu(2))gip and (sar(2))gip (10(-13) to 10(-8) mol/l) dose-dependently stimulated insulin secretion with significantly enhanced effects at 16.7 mmol/l compared with 5.6 mmol/l glucose. |
2003-07-11 |
2023-08-12 |
mouse |
| Victor A Gault, Finbarr P M O'Harte, Patrick Harriott, Peter R Flat. Degradation, cyclic adenosine monophosphate production, insulin secretion, and glycemic effects of two novel N-terminal Ala2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo. Metabolism: clinical and experimental. vol 52. issue 6. 2003-07-11. PMID:12800091. |
in obese diabetic (ob/ob) mice, gip and (sar(2))gip significantly increased (1.4-fold to 1.5-fold; p <.05) plasma insulin concentrations, whereas (abu(2))gip exerted only minor effects. |
2003-07-11 |
2023-08-12 |
mouse |
| T Vilsbøll, T Krarup, J Sonne, S Madsbad, A Vølund, A G Juul, J J Hols. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. The Journal of clinical endocrinology and metabolism. vol 88. issue 6. 2003-07-01. PMID:12788877. |
glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are incretin hormones secreted in response to meal ingestion, thereby enhancing postprandial insulin secretion. |
2003-07-01 |
2023-08-12 |
human |
| T Vilsbøll, T Krarup, J Sonne, S Madsbad, A Vølund, A G Juul, J J Hols. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. The Journal of clinical endocrinology and metabolism. vol 88. issue 6. 2003-07-01. PMID:12788877. |
we conclude: 1) that a decreased glp-1 secretion may contribute to impaired insulin secretion in type 2 diabetes mellitus, whereas gip and glp-1 secretion is normal in type 1 diabetic patients; and 2) that it is possible to modulate the beta-cell sensitivity to glucose in obese healthy subjects, and possibly also in type 2 diabetic patients, by giving them a large meal, compared with a small meal. |
2003-07-01 |
2023-08-12 |
human |
| Nathalie Pamir, Francis C Lynn, Alison M J Buchan, Jan Ehses, Simon A Hinke, J Andrew Pospisilik, Kazumasa Miyawaki, Yuichiro Yamada, Yutaka Seino, Christopher H S McIntosh, Raymond A Pederso. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. American journal of physiology. Endocrinology and metabolism. vol 284. issue 5. 2003-05-21. PMID:12540373. |
the incretins glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1) are gut hormones that act via the enteroinsular axis to potentiate insulin secretion from the pancreas in a glucose-dependent manner. |
2003-05-21 |
2023-08-12 |
mouse |
| P L Brubaker, D J Drucke. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors & channels. vol 8. issue 3-4. 2003-05-14. PMID:12529935. |
gip, a related member of the glucagon peptide superfamily, also regulates nutrient disposal via stimulation of insulin secretion. |
2003-05-14 |
2023-08-12 |
Not clear |
| Timothy J Kieffe. GIP or not GIP? That is the question. Trends in pharmacological sciences. vol 24. issue 3. 2003-04-08. PMID:12628351. |
because of the insulinotropic action of gip, this hormone has been considered as a potential therapy of type 2 diabetes, where insulin secretion is inadequate. |
2003-04-08 |
2023-08-12 |
mouse |
| V A Gault, P R Flatt, P Harriott, M H Mooney, C J Bailey, F P M O'Hart. Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide. The Journal of endocrinology. vol 176. issue 1. 2003-03-03. PMID:12525257. |
this enhanced glucose-lowering ability was coupled to a significantly raised (p<0.01) and more protracted insulin response compared with gip. |
2003-03-03 |
2023-08-12 |
mouse |
| T Vilsbøll, T Krarup, S Madsbad, J J Hols. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia. vol 45. issue 8. 2003-02-25. PMID:12189441. |
defective amplification of the late phase insulin response to glucose by gip in obese type ii diabetic patients. |
2003-02-25 |
2023-08-12 |
Not clear |
| T Vilsbøll, T Krarup, S Madsbad, J J Hols. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia. vol 45. issue 8. 2003-02-25. PMID:12189441. |
our investigation evaluated "early" (protocol 1) - and "late phase" (protocol 2) insulin and c-peptide responses to glp-1 and gip stimulation in patients with type ii diabetes. |
2003-02-25 |
2023-08-12 |
Not clear |
| Jens J Hols. Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1? BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. vol 16. issue 3. 2003-02-24. PMID:12102645. |
gastric inhibitory polypeptide (gip, also called glucose-dependent insulinotropic polypeptide) and glucagon-like peptide-1 (glp-1) are peptide hormones from the gut that enhance nutrient-stimulated insulin secretion (the 'incretin' effect). |
2003-02-24 |
2023-08-12 |
mouse |
| Juris J Meier, Michael A Nauck, Wolfgang E Schmidt, Baptist Gallwit. Gastric inhibitory polypeptide: the neglected incretin revisited. Regulatory peptides. vol 107. issue 1-3. 2003-02-13. PMID:12137960. |
however, the physiological importance of gip in the regulation of insulin secretion has been shown to even exceed that of glp-1. |
2003-02-13 |
2023-08-12 |
Not clear |
| Francis C Lynn, Stephen A Thompson, J Andrew Pospisilik, Jan A Ehses, Simon A Hinke, Nathalie Pamir, Christopher H S McIntosh, Raymond A Pederso. A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 17. issue 1. 2003-02-10. PMID:12475913. |
glucose-dependent insulinotropic polypeptide (gip) is secreted postprandially and acts in concert with glucose to stimulate insulin secretion from the pancreas. |
2003-02-10 |
2023-08-12 |
rat |
| V A Gault, J C Parker, P Harriott, P R Flatt, F P M O'Hart. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. The Journal of endocrinology. vol 175. issue 2. 2003-01-06. PMID:12429050. |
in brin-bd11 cells, gip(3-42) was significantly less potent at stimulating insulin secretion (1.9- to 3.2-fold; p<0.001), compared with native gip and significantly inhibited gip-stimulated (10(-7) m) insulin secretion with maximal inhibition (48.8+/-6.2%; p<0.001) observed at 10(-7) m. in (ob/ob) mice, administration of gip(3-42) significantly inhibited gip-stimulated insulin release (2.1-fold decrease; p<0.001) and exaggerated the glycaemic excursion (1.4-fold; p<0.001) induced by a conjoint glucose load. |
2003-01-06 |
2023-08-12 |
mouse |